CDC20 and prostate cancer: Moreover, these trials lack sequencing information from patient samples, thereby limiting the exploration of the correlation between CDC20 expression levels and immunotherapy efficacy.Nevertheless, more preclinical models, such as transgenic murine models of prostate cancer, are needed to confirm further the effects of CDC20 depletion and the synergistic effects with various ICIs.